368 related articles for article (PubMed ID: 12852367)
21. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
23. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
Pileri A; Delfino C; Grandi V; Pimpinelli N
Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425
[TBL] [Abstract][Full Text] [Related]
24. Acitretin for the treatment of cutaneous T-cell lymphoma.
Cheeley J; Sahn RE; DeLong LK; Parker SR
J Am Acad Dermatol; 2013 Feb; 68(2):247-54. PubMed ID: 22917895
[TBL] [Abstract][Full Text] [Related]
25. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
26. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Licata AG; Wilson LD; Braverman IM; Feldman AM; Kacinski BM
Arch Dermatol; 1995 Apr; 131(4):432-5. PubMed ID: 7726585
[TBL] [Abstract][Full Text] [Related]
27. Treatment of cutaneous T cell lymphoma: current status and future directions.
Apisarnthanarax N; Talpur R; Duvic M
Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
[TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
[TBL] [Abstract][Full Text] [Related]
29. Treatment of cutaneous T-cell lymphoma.
Zackheim HS
Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
[TBL] [Abstract][Full Text] [Related]
30. Full clinical recovery after topical acyclovir treatment of Epstein-Barr virus associated cutaneous B-cell lymphoma in patient with mycosis fungoides.
Copur MS; Deshpande A; Mleczko K; Norvell M; Hrnicek GJ; Woodward S; Frankforter S; Mandolfo N; Fu K; Chan WC
Croat Med J; 2005 Jun; 46(3):458-62. PubMed ID: 15861527
[TBL] [Abstract][Full Text] [Related]
31. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
el-Azhary RA; Bouwhuis SA
Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
[TBL] [Abstract][Full Text] [Related]
32. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
33. The role of phototherapy in cutaneous T-cell lymphoma.
Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
[TBL] [Abstract][Full Text] [Related]
34. Treatment of cutaneous T-cell lymphoma with retinoids.
Zhang C; Duvic M
Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
[TBL] [Abstract][Full Text] [Related]
35. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
36. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
37. Combination treatment in CTCL: the current role of bexarotene.
Delfino C; Grandi V; Pileri A; Rupoli S; Quaglino P; Alterini R; Goteri G; Canafoglia L; Pimpinelli N
G Ital Dermatol Venereol; 2012 Dec; 147(6):573-80. PubMed ID: 23149703
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
[TBL] [Abstract][Full Text] [Related]
39. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
40. [Therapy of cutaneous T-cell lymphomas].
Rappersberger K; Ortel B; Forstinger C; Wolff K
Wien Klin Wochenschr; 1994; 106(10):300-8. PubMed ID: 8053197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
